CatalystMarker
← board

ACUT

distress 2/10 · well-funded / low risk
$0.18-12%today-92% from 52w high
accustem.com4 employeesFounded 2013New York, NYBiotechnology
Revenue
pre-revenue
Liquidity
$0M
Runway
Shares 1y
0%

Price & events

-72.3% over 6M
$0.16$0.40$0.65Jan 26Apr 26Jul 2658k
CatalystRating changeDilutionFinancingdashed = today
-12.2%
1D
-1.9%
1W
-13.0%
1M
-43.7%
3M
-72.3%
6M
-82.2%
1Y
-53.8%
2Y
5Y
-91.0%
All

Overview

Market Cap
$2.89M
Volume
827
52 Week Range
$0.16 – $2.21
Total Shares
16.07M
Float Shares
11.43M
% Held by Insiders
50.92%
% Held by Institutions
0.00%
RVOL
0.16x
Beta
1.88

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 16,072,267 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.